Robeco Institutional Asset Management B.V. Cuts Stake in Zimmer Biomet Holdings, Inc. $ZBH

Robeco Institutional Asset Management B.V. trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 46.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,238 shares of the medical equipment provider’s stock after selling 10,504 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Zimmer Biomet were worth $1,116,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Garde Capital Inc. purchased a new stake in shares of Zimmer Biomet during the 1st quarter valued at about $29,000. Washington Trust Advisors Inc. purchased a new stake in shares of Zimmer Biomet during the 1st quarter valued at about $30,000. Columbia River Financial Group LLC purchased a new position in shares of Zimmer Biomet in the first quarter worth approximately $30,000. Accent Capital Management LLC purchased a new position in shares of Zimmer Biomet in the first quarter worth approximately $35,000. Finally, Cullen Frost Bankers Inc. boosted its holdings in shares of Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 305 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a report on Saturday, September 27th. Raymond James Financial raised their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. UBS Group raised their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a report on Thursday, September 18th. Finally, Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $112.89.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Trading Up 0.3%

ZBH stock opened at $99.12 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72. The stock has a market capitalization of $19.63 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.67. The firm’s fifty day simple moving average is $101.01 and its two-hundred day simple moving average is $98.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. During the same quarter in the previous year, the business posted $2.01 earnings per share. The business’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.